Back to Semaglutide research
semaglutide glp 1 agonist other 2026-02 ClinicalTrials

Semaglutide Explored as Potential Treatment for Polycystic Ovary Syndrome

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Study Design

Population
Not specified in the digest.
Intervention
Semaglutide, dose, route, and duration not specified.
Outcome
Not specified in the digest.

Abstract

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy NCT ID: NCT06222437 Status: WITHDRAWN Sponsor: Methodist Health System Phase: PHASE1 Start: 2026-02 | Completion: 2027-02 Enrollment: 0 (ACTUAL) Conditions: Polycy…

semaglutide glp 1 agonist
Source: clinicaltrials:NCT06222437 · Ingested 2026-05-01 · Digest: gemini-2.5-flash